These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22867718)

  • 1. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
    Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
    Clay PA; Thompson TD; Markowitz LE; Ekwueme DU; Saraiya M; Chesson HW
    Vaccine; 2023 Mar; 41(14):2376-2381. PubMed ID: 36907737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
    Insinga RP; Dasbach EJ; Elbasha EH
    Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
    Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
    Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
    PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
    Thomas TL
    Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The healthcare costs of treating human papillomavirus-related cancers in Norway.
    Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
    BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE; Vuocolo S
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
    BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic burden of noncervical human papillomavirus disease in the United States.
    Hu D; Goldie S
    Am J Obstet Gynecol; 2008 May; 198(5):500.e1-7. PubMed ID: 18455524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
    Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
    J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018.
    Chesson HW; Laprise JF; Brisson M; Martin D; Ekwueme DU; Markowitz LE
    Sex Transm Dis; 2021 Apr; 48(4):278-284. PubMed ID: 33492104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
    Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
    PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The disease burden of human papillomavirus in men is substantial and can potentially be prevented].
    Kiellberg Larsen H; Kofoed K; Sand C
    Ugeskr Laeger; 2013 Feb; 175(6):349-53. PubMed ID: 23402241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
    BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
    Ginindza TG; Sartorius B; Dlamini X; Östensson E
    PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the health burden of HPV infection through vaccination.
    Soper D
    Infect Dis Obstet Gynecol; 2006; 2006 Suppl():83084. PubMed ID: 16967913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S;
    Vaccine; 2013 Dec; 31 Suppl 5():F1-31. PubMed ID: 24331745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.